1402607-92-4

Basic information

• Product Name: N-((R)-(2-chlorophenyl)(7-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)-2-pyridinyl)-1-benzothiophen-2-yl)methyl)-3,4-dihydro-2H-1,5-benzodioxepine-7-sulfonamide
• Synonyms: N-((R)-(2-chlorophenyl)(7-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)-2-pyridinyl)-1-benzothiophen-2-yl)methyl)-3,4-dihydro-2H-1,5-benzodioxepine-7-sulfonamide
• CAS NO: 1402607-92-4
• Molecular Weight: 729.12
• Mol File: 1402607-92-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-((R)-(2-chlorophenyl)(7-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)-2-pyridinyl)-1-benzothiophen-2-yl)methyl)-3,4-dihydro-2H-1,5-benzodioxepine-7-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-((R)-(2-chlorophenyl)(7-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)-2-pyridinyl)-1-benzothiophen-2-yl)methyl)-3,4-dihydro-2H-1,5-benzodioxepine-7-sulfonamide(1402607-92-4)
• EPA Substance Registry System: N-((R)-(2-chlorophenyl)(7-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)-2-pyridinyl)-1-benzothiophen-2-yl)methyl)-3,4-dihydro-2H-1,5-benzodioxepine-7-sulfonamide(1402607-92-4)

Safety Data

• Hazardous Substances Data: 1402607-92-4(Hazardous Substances Data)

Upstream product

• 65287-34-5 2-chloropyridine-4-carbonyl chloride 
• 1402599-00-1 2-(2-(2-((R)-amino(2-chlorophenyl)methyl)-1-benzothiophen-7-yl)-4-pyridinyl)-1,1,1,3,3,3-hexafluoro-2-propanol hydrochloride 
• 321309-38-0 3,4-dihydro-2H-1,5-benzodioxepine-7-sulfonyl chloride 
• 1402598-94-0 N-((S,1E)-(2-chlorophenyl)methylidene)-2-methyl-2-propanesulfinamide 
• 1402599-02-3 2-(2-chloro-4-pyridinyl)-1,1,1,3,3,3-hexafluoro-2-propanol 

Relevant articles and documents

BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES

The present invention relates to compounds of formula I or II, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.